Rashes are a common side effect of some prostate cancer treatments. Rarely, they may be caused by cancer cells.

Many other conditions can mimic the symptoms of prostate cancer, both in its early or advanced stages. Here's what you need ...

Formula 1 legend Eddie Jordan has died from cancer at the age of 76—just a year after first learning he had the disease. His devastated family announced the sad news on March 19, adding that the ...

Bladder cancer affects over 52,000 men and women in the United States on an annual basis, and more than 12,000 people die each year from this disease. It is the fourth most common cancer in men in ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

ABOUT 55,000 new prostate cancer cases are recorded every year in the UK. Bladder cancer is less common, with around 10,500 new cases. For both types, cancer can start in one area of the body and ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

The FDA has approved Imfinzi (durvalumab) as neoadjuvant and adjuvant treatment in patients with muscle-invasive bladder cancer.

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.

Durvalumab plus gemcitabine and cisplatin significantly improved event free survival and overall survival compared with gemcitabine and cisplatin. The Food and Drug Administration (FDA) has ...